兄弟科技(002562.SZ):“碘造影劑項目”投產
格隆匯 10 月 13日丨兄弟科技(002562.SZ)公佈,公司自有資金建設項目“年產1000噸碘造影劑及其中間體建設項目—一期工程”(“碘造影劑項目”,一期工程為年產400噸碘造影劑及其中間體)在經過一段時間的調試、試生產,現已符合投產條件。
“碘造影劑項目”的相關產品廣泛應用於加強型CT造影檢查。“碘造影劑項目”投產後,公司將在現有的單一維生素原料藥業務基礎上,增加碘造影劑原料藥及其中間體產品,實現從精細化工向醫藥中間體、醫藥原料藥垂直一體化的戰略。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.